As of close of business last night, Lucira Health Inc.’s stock clocked out at $0.33, up 25.38% from its previous closing price of $0.26. In other words, the price has increased by $+0.0666 from its previous closing price. On the day, 19842606 shares were traded. LHDX stock price reached its highest trading level at $0.4495 during the session, while it also had its lowest trading level at $0.2900.
To gain a deeper understanding of LHDX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.80 and its Current Ratio is at 1.50. In the meantime, Its Debt-to-Equity ratio is 0.48 whereas as Long-Term Debt/Eq ratio is at 0.48.
Upgrades & Downgrades
On April 13, 2021, BofA Securities Downgraded its rating to Underperform which previously was Neutral but kept the price unchanged to $9.
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 20 when Allen Anthony Joseph sold 4,263 shares for $0.16 per share. The transaction valued at 682 led to the insider holds 144,925 shares of the business.
Narido Richard Clavano sold 1,583 shares of LHDX for $570 on Dec 01. The Interim CFO now owns 107,293 shares after completing the transaction at $0.36 per share. On Nov 28, another insider, Kashmolah Ghazi, who serves as the Ex VP & Chief Quality Officer of the company, sold 7,537 shares for $0.42 each. As a result, the insider received 3,166 and left with 139,103 shares of the company.
For the stock, the TTM Price-to-Sale (P/S) ratio is 0.05 while its Price-to-Book (P/B) ratio in mrq is 0.22.
Stock Price History:
Over the past 52 weeks, LHDX has reached a high of $5.86, while it has fallen to a 52-week low of $0.11. The 50-Day Moving Average of the stock is 0.3536, while the 200-Day Moving Average is calculated to be 1.6700.
It appears that LHDX traded 4.67M shares on average per day over the past three months and 5.37M shares per day over the past ten days. A total of 40.22M shares are outstanding, with a floating share count of 36.67M. Insiders hold about 3.40% of the company’s shares, while institutions hold 57.10% stake in the company. Shares short for LHDX as of Oct 13, 2022 were 71.41k with a Short Ratio of 0.05M, compared to 84.41k on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 0.18% and a Short% of Float of 0.41%.
As of right now, 3 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.38 for the current quarter, with a high estimate of -$0.19 and a low estimate of -$0.54, while EPS last year was -$0.47. The consensus estimate for the next quarter is $0.13, with high estimates of $0.23 and low estimates of -$0.03.
Analysts are recommending an EPS of between -$0.22 and -$0.77 for the fiscal current year, implying an average EPS of -$0.41. EPS for the following year is -$1.09, with 2 analysts recommending between -$0.39 and -$1.79.
In the current quarter, 2 analysts expect revenue to total $32.79M. It ranges from a high estimate of $33.38M to a low estimate of $32.2M. As of the current estimate, Lucira Health Inc.’s year-ago sales were $18.3M, an estimated increase of 79.20% from the year-ago figure. For the next quarter, 3 analysts are estimating revenue of $90.01M, an increase of 47.30% less than the figure of $79.20% in the same quarter last year. There is a high estimate of $110.02M for the next quarter, whereas the lowest estimate is $80M.
A total of 3 analysts have provided revenue estimates for LHDX’s current fiscal year. The highest revenue estimate was $258.84M, while the lowest revenue estimate was $230M, resulting in an average revenue estimate of $239.96M. In the same quarter a year ago, actual revenue was $93.06M, up 157.90% from the average estimate. Based on 2 analysts’ estimates, the company’s revenue will be $207.5M in the next fiscal year. The high estimate is $220M and the low estimate is $195M. The average revenue growth estimate for next year is down -13.50% from the average revenue estimate for this year.